Market Overview:
The global bile duct cancer drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of bile duct cancer, rising awareness about available treatment options, and the launch of novel drugs. Based on type, the global bile duct cancer drug market is segmented into cabozantinib S-malate, elpamotide, exatecan mesylate, LY-2801653, NUC-1031 and others. Cabozantinib S-malate held a major share of the global market in 2017 and is expected to maintain its dominance during the forecast period. This can be attributed to its high efficacy in treating advanced stages of bile duct cancer. Based on application, the global market is segmented into hospital pharmacies/clinics/outpatient settings and others (includes research institutes). Clinics are expected to hold a dominant share of this market during the forecast period owing to their growing demand for targeted therapies for various cancers including bile duct cancer.
Product Definition:
Bile duct cancer is a type of cancer that starts in the cells that line the bile ducts. The bile ducts are thin tubes that carry bile from the liver to the gallbladder and intestines. Bile helps digest food and remove waste products from the body.
Biliary tract cancers (BTC) are rare, accounting for only 1-2% of all cancers in adults. The incidence increases with age, and it is more common in men than women (1.3:1). About 90% of cases occur in people aged 55 years or older at diagnosis; however, BTC can occur at any age [].
Cholangiocarcinoma (CCA), which arises from epithelial cells lining small intrahepatic biliary ductules (ductules within liver), accounts for 60-75% of all BTC []. CCA most commonly presents as a painless mass located centrally within the upper abdomen on imaging studies. Other common presenting symptoms include jaundice, weight loss, fever, and pruritus.
The mainstay of treatment for patients with metastatic CCA is chemotherapy; however many patients will eventually require surgery to resect their tumor(s).
Cabozantinib S-malate:
Cabozantinib S-malate is a novel targeted drug for the treatment of patients with metastatic bile duct cancer. It works by blocking some of the important signals that help cancer cells to grow and multiply. The drug has shown potent activity in vitro and in vivo as it potently blocks both HER2-positive and -negative breast cancer cell lines, while having no effect on noncancerous cells.
Elpamotide:
Elpamotide is a novel, first-in-class oral drug that targets and enhances the activity of lysosomal enzymes. These enzymes are responsible for the breakdown (lysis) of proteins in the body, including some cancer-related proteins.
Application Insights:
The others segment held the largest share of the global market in 2017. This includes Bile Duct Cancer (CIS, locally advanced and metastatic), Primary liver cancer, Cholangiocarcinoma, Osteosarcoma and other cancers. The primary liver cancer application segment is expected to witness lucrative growth during the forecast period owing to increasing prevalence of alcoholic and non-alcoholic liver diseases globally.
Biliary stromal tumor (IST) is another significant application segment that is expected to grow at a significant rate during the forecast period due to rising awareness about early diagnosis coupled with improved treatment options such as cabozantinib S-malate in near future.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of players, high adoption rate for new therapies, and favorable reimbursement policies. The region is expected to maintain its dominance over the forecast period due to factors such as increasing incidence rates and rising demand for cabozantinib malate. Asia Pacific is expected to witness lucrative growth during the forecast period owing to growing awareness about bile duct cancer, improving healthcare infrastructure especially in developing countries like India & China, and increasing investment by manufacturers. In addition, approval of cabozantinib malate by regulatory bodies such as FDA & EMEA will further boost revenue generation in this region.
The key companies operating in this space are AstraZeneca; Pfizer Inc.; Merck Group; Celgene Corporation; Bristol-Myers Squibb Company; AbbVie Inc.; Novartis AG., among others (Table 1).
Growth Factors:
- Increasing incidence of bile duct cancer
- Growing demand for better treatment options for bile duct cancer
- Rising awareness about available treatment options for bile duct cancer
- Technological advancements in the field of diagnosis and treatment of bile duct cancer 5. Availability of funding for research and development activities related to the treatment of bile duct cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Bile Duct Cancer Drug Market Research Report
By Type
Cabozantinib S-malate, Elpamotide, Exatecan Mesylate, LY-2801653, NUC-1031, Others
By Application
Hospital, Clinic, Others
By Companies
Ariad Pharmaceuticals, Inc., ArQule, Inc., Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Aslan Pharmaceuticals Pte. Ltd., Bavarian Nordic A/S, Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Ariad Pharmaceuticals, Inc., Celgene Corporation, CellAct Pharma GmbH, Cellceutix Corporation, Cellular Biomedicine Group, Inc., Concordia Healthcare Corp.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
133
Number of Tables & Figures
94
Customization Available
Yes, the report can be customized as per your need.
Global Bile Duct Cancer Drug Market Report Segments:
The global Bile Duct Cancer Drug market is segmented on the basis of:
Types
Cabozantinib S-malate, Elpamotide, Exatecan Mesylate, LY-2801653, NUC-1031, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Ariad Pharmaceuticals, Inc.
- ArQule, Inc.
- Array BioPharma Inc.
- Arrien Pharmaceuticals, LLC
- Aslan Pharmaceuticals Pte. Ltd.
- Bavarian Nordic A/S
- Bayer AG
- Blueprint Medicines Corporation
- Boehringer Ingelheim GmbH
- Boston Biomedical, Inc.
- Ariad Pharmaceuticals, Inc.
- Celgene Corporation
- CellAct Pharma GmbH
- Cellceutix Corporation
- Cellular Biomedicine Group, Inc.
- Concordia Healthcare Corp.
Highlights of The Bile Duct Cancer Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cabozantinib S-malate
- Elpamotide
- Exatecan Mesylate
- LY-2801653
- NUC-1031
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bile Duct Cancer Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bile duct cancer is a type of cancer that starts in the bile ducts. The bile ducts are small tubes that carry bilirubin and other substances from the liver to the small intestine. Bile duct cancer can occur anywhere in the bile duct system, but most often it occurs in the upper part of the system (the common bileduct).
Some of the major companies in the bile duct cancer drug market are Ariad Pharmaceuticals, Inc., ArQule, Inc., Array BioPharma Inc., Arrien Pharmaceuticals, LLC, Aslan Pharmaceuticals Pte. Ltd., Bavarian Nordic A/S, Bayer AG, Blueprint Medicines Corporation, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Ariad Pharmaceuticals, Inc., Celgene Corporation, CellAct Pharma GmbH, Cellceutix Corporation, Cellular Biomedicine Group, Inc., Concordia Healthcare Corp..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bile Duct Cancer Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bile Duct Cancer Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bile Duct Cancer Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bile Duct Cancer Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bile Duct Cancer Drug Market Size & Forecast, 2020-2028
4.5.1 Bile Duct Cancer Drug Market Size and Y-o-Y Growth
4.5.2 Bile Duct Cancer Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cabozantinib S-malate
5.2.2 Elpamotide
5.2.3 Exatecan Mesylate
5.2.4 LY-2801653
5.2.5 NUC-1031
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bile Duct Cancer Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bile Duct Cancer Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cabozantinib S-malate
9.6.2 Elpamotide
9.6.3 Exatecan Mesylate
9.6.4 LY-2801653
9.6.5 NUC-1031
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cabozantinib S-malate
10.6.2 Elpamotide
10.6.3 Exatecan Mesylate
10.6.4 LY-2801653
10.6.5 NUC-1031
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cabozantinib S-malate
11.6.2 Elpamotide
11.6.3 Exatecan Mesylate
11.6.4 LY-2801653
11.6.5 NUC-1031
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cabozantinib S-malate
12.6.2 Elpamotide
12.6.3 Exatecan Mesylate
12.6.4 LY-2801653
12.6.5 NUC-1031
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cabozantinib S-malate
13.6.2 Elpamotide
13.6.3 Exatecan Mesylate
13.6.4 LY-2801653
13.6.5 NUC-1031
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bile Duct Cancer Drug Market: Competitive Dashboard
14.2 Global Bile Duct Cancer Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Ariad Pharmaceuticals, Inc.
14.3.2 ArQule, Inc.
14.3.3 Array BioPharma Inc.
14.3.4 Arrien Pharmaceuticals, LLC
14.3.5 Aslan Pharmaceuticals Pte. Ltd.
14.3.6 Bavarian Nordic A/S
14.3.7 Bayer AG
14.3.8 Blueprint Medicines Corporation
14.3.9 Boehringer Ingelheim GmbH
14.3.10 Boston Biomedical, Inc.
14.3.11 Ariad Pharmaceuticals, Inc.
14.3.12 Celgene Corporation
14.3.13 CellAct Pharma GmbH
14.3.14 Cellceutix Corporation
14.3.15 Cellular Biomedicine Group, Inc.
14.3.16 Concordia Healthcare Corp.
